Highlights

  • 1

    Determine whether the Breast Cancer Index BCI (H/I) status (High vs Low) is predictive of the benefit of 10 years versus 5 years of tamoxifen.

  • 2

    Evaluate whether BCI (H/I), as a continuous index, demonstrates a statistically significant treatment to biomarker interaction with extended tamoxifen treatment

Summary

Detailed clinical data presentation of using this new dignostic assay we are able to identify a group of 10% of patients who do benefit extending endocrine therapy to 10 years instead of 5 years. This study shows that we can now identify which patients can safely discontinue treatment at 5 years avoiding the risks of side effects. We have reached level 1B evidence and this diagnostic test may be implemented in the clinic.

This event is sponsored by: :

Interviewee

User

John Bartlett

Edinburgh, Scotland

Personalized medicine requires personalized diagnostics. As the impact of the deep molecular characterization of cancer and other diseases is translat...

Interviewer

User

Antoine Abugaber

Niagara Falls, Ontario

While in the Medical Department in large Pharma he held the positions of; Director of Clinical Operations, International Clinical Research and Develop...

Comments (0)